Patents by Inventor David Owerbach

David Owerbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
    Patent number: 5059519
    Abstract: DQ beta gene oligonucleotides consisting essentially of the sequence GGCCGCCTGCCGCCGAG or of the sequence GCTGGGGCTGCCTGCCG and the use of such oligonucleotides in a method for assaying for a polymorphic region associated with Type I diabetes mellitus in humans.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: October 22, 1991
    Assignee: University of Massachusetts Medical School
    Inventor: David Owerbach
  • Probes for the determination of the proclivity for development of autoimmune diseases
    Patent number: 4965189
    Abstract: DQ beta gene oligonucleotides selected from the group consisting of(1) GAGAGGAGTACGCACGCTT,(2) GCTGGGGCCGCCTGCCGCC,(3) AGGACCCGGGCGGAGTTGG,(4) GAGAAGAGATCGTGCGCTT,(5) GCTGGGGCTGCCTGCCGCC and(6) AGGAAACGGGCGGCGGTGG.Such oligonucleotides are useful in methods for detecting the proclivity in a human for development of Type I diabetes mellitus.
    Type: Grant
    Filed: July 1, 1986
    Date of Patent: October 23, 1990
    Assignee: University of Massachusetts Medical School
    Inventor: David Owerbach
  • Method for the determination of liability in human individuals to develop atherosclerosis
    Patent number: 4623619
    Abstract: Liability in human individuals to develop non-insulin-dependent diabetes mellitus (NIDDM) and/or atherosclerosis is determined by restriction enzyme mapping of DNA from a human individual using a probe selected from the group consisting of(i) cDNA complementary to the mRNA coding for the human insulin,(ii) human genomic DNA containing the actual insulin gene,(iii) DNA sequences of human genomic DNA located within 20.times.10.sup.6 base pairs from the insulin gene in either direction,and examining the distribution of DNA fragments for the appearance of insertion sequences of approximately 1600 to 2300 base pairs (U alleles) the occurrence of which indicates a liability for said individual to develop elevated blood glucose concentrations and/or atherosclerosis and in homozygous form a liability to develop NIDDM.
    Type: Grant
    Filed: February 18, 1983
    Date of Patent: November 18, 1986
    Assignee: Nordisk Insulinlaboratorium
    Inventors: David Owerbach, Jorn Nerup